Nutex Health, Inc.

NUTX

$192.00

+2.49%

2026-09-02 16:00:01 EDT+$4.66

Healthcare

Medical - Care Facilities

NASDAQ

Active Trading

Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population ...

Price Action of NUTX

$192.00

+2.49%+$4.66

High—

Low—

52W High-5.9%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Nutex Health, Inc. is a physician-led healthcare management and operations company that aims to make concierge-level healthcare accessible to communities across the United States. Founded in 2011 by Dr. Thomas T. Vo, the company has grown to operate 21 locations in eight states, primarily focusing on micro-hospitals, which are small-format, ...Nutex Health, Inc. is a physician-led healthcare management and operations company that aims to make concierge-level healthcare accessible to communities across the United States. Founded in 2011 by Dr. Thomas T. Vo, the company has grown to operate 21 locations in eight states, primarily focusing on micro-hospitals, which are small-format, full-service hospitals that provide emergency and inpatient care. The company's Hospital Division develops and manages these micro-hospitals and specialized medical centers, while its Population Health Management Division creates and manages independent physician associations (IPAs) and management services organizations (MSOs) that offer administrative and operational support to hospitals and physician groups. A key differentiator is its proprietary cloud-based technology platform, which integrates patient and provider data from various sources to create a holistic view, enabling more effective and coordinated care. Financially, Nutex Health has demonstrated strong performance with a market cap of over $1.1 billion, a revenue per share of $126.35, and a net profit margin of 21.2%. The company has a current ratio of 4.996, indicating strong liquidity, and a low debt-to-equity ratio of 0.623, suggesting moderate leverage. With approximately 1,005 full-time employees, Nutex Health is committed to expanding its footprint and enhancing healthcare delivery through innovation and operational excellence. The company is publicly traded on NASDAQ and continues to focus on growth through acquisitions and organic development, driven by a mission to provide high-quality, patient-centered care.ExpandCollapse

Founded

2011

Employees

1037

CEO

Thomas T. Vo

Full Name

Nutex Health, Inc.

Sector

Healthcare

Industry

Medical - Care Facilities

ROE

51.88%

Market Cap

$1.32B

Current Ratio

5.00

WACC

11.95%

ROIC

34.16%

Contact Information

https://www.nutexhealth.com

713 660 0557

1776 Yorktown Street, Houston, TX 77056

Key Metrics of NUTX

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.32B

ROCE

43.0%

EV / EBITDA

3.91x

+6.7% YoY

FCF Yield

20.2%

-3.3% YoY

Cash Conversion Cycle

148.7d

Current Ratio

5.00

Quick take

TTM —

Positive CCC

Financial Highlights of NUTX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

51.3%

Net Margin

21.2%

P/E Ratio

7.54x

n/a

Debt / Equity

0.88

n/a

Current Ratio

5.00

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of NUTX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $5.96 · Revenue $214.12M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $6.47 · Revenue $228.30M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $28.30 · Revenue $869.68M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $7.46 · Revenue $236.65M · 1 analysts

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $9.38 · Revenue $210.75M
View filing
Apr 30, 2026
Q1 FY2026 · Results reported
EPS $6.52 · Revenue $216.49M
View filing
Mar 5, 2026
FY2025 · Annual results
EPS $10.48 · Revenue $875.26M
View filing
Nov 19, 2025
Q3 FY2025 · Results reported
EPS $7.76 · Revenue $267.80M
View filing
Nov 18, 2025
Q2 FY2025 · Results reported
EPS $-3.02 · Revenue $243.99M
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $2.56 · Revenue $211.79M

Financial Statements of NUTX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$875.3M	+82.4%	-2.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$70.8M	+35.7%	+40.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+50.8%	+24.1%	+58.2%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+31.5%	+15.7%	+53.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+8.1%	-25.6%	+44.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$245.6M	+1077.9%	-57.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+28.1%	+545.9%	-56.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	106.7%	-54.1%	-12.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.41x	+64.3%	+59.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$918.5M	+40.2%	+0.8%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	10.48 vs 14.07	-25.5%	9.38 vs 4.95	+89.3%
Revenue Surprise	$875.3M vs $982.4M	-10.9%	$210.8M vs $215.0M	-2.0%

Insider Transactions of NUTX

Acquisitions (A)

Since Apr 23, 2026

Disposals (D)

Since Apr 23, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 31, 2026	Jaumot Frank E	director	Common Stock	A	603	—
Jul 31, 2026	Grenas Cheryl Yvonne	director	Common Stock	A	603	—
Jul 31, 2026	Saunders Scott J	director	Common Stock	A	603	—
Jul 31, 2026	Reed Michael Lee	director	Common Stock	A	603	—
Jun 4, 2026	Spears Kelvin	director	Common Stock	A	2,519	—

Earnings Call Transcript of NUTX

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Greetings, and welcome to the Nutex Health's 2026 Second Quarter 10-Q Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Vivian Sanders, Corporate Director of Marketing. Please go ahead. Vivian Sanders: Good morning, everyone, and welcome to Nutex Health, Inc.'s Second Quarter 2026 Earnings Call. My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter. Please note that this call is being recorded for future reference. Joining me this morning are the key leaders driving Nutex Health forward. Our Chairman and CEO, Dr. Tom Vo; our Chief Financial Officer, Jon Bates; our President, Dr. Warren Hosseinion; and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance, strategies and vision, after which we'll open the floor for your questions. Before I turn things over to Dr. Vo, I'd like to take a moment to address a few important points. Today's discussion may include forward-looking statements, which reflect management's current expectations about our future performance. These statements are based on what we know today, but they are subject to risks, uncertainties and other factors that could cause our actual results to differ from what we'll share. For a deeper dive into these forward-looking statements and the factors that may influence them, I encourage you to review the press release and Form 10-Q filed earlier this week as well as our various SEC filings. You'll find all the details there. Additionally, we may reference non-GAAP financial measures such as adjusted EBITDA during the call. For those interested in how these metrics reconcile to GAAP standards, please refer to the press release and Form 10-Q, where that information is included. With those housekeeping items out of the way, it's my pleasure to hand the call over to Dr. Tom Vo, our Founder and Chief Executive Officer. Dr. Tom Vo, the floor is yours. Thomas Vo: Thank you, Vivian, and good morning, everyone. I am happy to join you today to review Nutex Health's second quarter 2026 results. It was an active quarter, marked by strong financial results, important reimbursement developments and continued progress on our growth pipeline, both internally with hospital volume and acuity as well as new pipeline developments. Let me begin with our first 6 months financial and operational performance. For the first 2 quarters of 2026, total revenue reached $427.2 million, a slight 6% decrease from $455.8 million for the same period in 2025. This is primarily due to timing from accrual to cash collections, as Jon will further explain. Net income attributable to Nutex increased to $112.6 million for the first 2 quarters of 2026, a 3,100% increase from $3.5 million for the same …

Leadership Team of NUTX

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Thomas T. Vo	Chairman of the Board & Chief Executive Officer	USD 1,527,470	—	1973	Active
Warren Hosseinion	President & Director	USD 1,199,516	—	1972	Active
Jon C. Bates	Chief Financial Officer	USD 684,536	Male	1971	Active
Michael Chang	Chief Medical Officer	USD 549,097	—	1972	Active
Wesley Bamburg FACHE	Chief Operating Officer	USD 392,722	Male	—	Active
Elisa Michael Luqman	Chief Legal Officer of Healthcare & Board Secretary	USD 251,334	Female	1964	Active
LaTanya Brackens	Director of Compliance	—	Female	—	Active
Sarah Wallace	Director of Human Resources	—	Female	—	Active
Jennifer Rodriguez	Investor & Public Relations Manager	—	Female	—	Active
Vivian Sanders	Director of Marketing	—	Female	—	Active

Recent News of NUTX

GuruFocus2 days agoNeutral

Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data

Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data PR Newswire HOUSTON

PRNewsWire2 days agoNeutral

Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data

Free case evaluations for individuals affected by the Nutex Health cyberattack claimed by The Gentlemen ransomware group HOUSTON, Sept. 1, 2026 /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a cyberattack on Nutex Health Inc. (NASDAQ: NUTX).

Zacks Investment Research3 days agoNeutral

Nutex Health Inc. (NUTX) is a Great Momentum Stock: Should You Buy?

Does Nutex Health Inc. (NUTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

PRNewsWire4 days agoNeutral

Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026

HOUSTON, Aug. 31, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the awards and honors earned by its hospitals during the second quarter of 2026. Nutex Health hospitals have long served as trusted health care providers in their communities.

Zacks Investment Research8/27/2026Neutral

4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns

NUTX, RCMT, RELY and BDC boast strong net margins, positive earnings estimate revisions and bullish analyst ratings that signal upside.

Historical Employee Count of NUTX

Current

944

Change

+18.00%

Minimum

Maximum

1,150

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	944	10-K	Mar 5, 2026	View
Dec 31, 2024	800	10-K	Mar 31, 2025	View
Dec 31, 2023	800	10-K	Mar 29, 2024	View
Dec 31, 2022	1,150	10-K	Mar 3, 2023	View
Dec 31, 2021	24	10-K	Mar 31, 2022	View

Related stocksMedical - Care Facilities

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Nutex Health, Inc.